Salute e Benessere
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025
- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced the presentation of clinical study data from the Company’s lead investigational medicine in development, varoglutamstat, in a late-breaking poster today, November 6, 2025, at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas.
The poster titled “Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial” featured Phase 2 clinical study data underscoring varoglutamstat’s unique ability to stabilize and even improve kidney function, as measured by eGFR values.
Results from Vivoryon’s VIVIAD Phase 2b study previously showed that reduction of the anti-inflammatory biomarker pE-CCL2 was associated with an improvement of kidney function as measured by eGFR in study participants with and without diabetes at a dose group level. In line with these results, the poster highlights further analyses of total population data from the VIVIAD study evaluating the correlation of pE-CCL2 levels and eGFR slope on an individual participant level, which revealed a statistically significant correlation between the change from baseline in pE-CCL2 serum levels at week 48 and the eGFR slope over time. Specifically, a decrease in pE-CCL2 was significantly correlated with a positive (improved) eGFR slope.
“We are truly grateful for the opportunity to share our consistently compelling results with world leading scientific and medical experts in the kidney field at ASN Kidney week, considered to be the world’s premier nephrology congress,” said Frank Weber, MD, CEO of Vivoryon. “Inflammation is known to be a key driver in diabetic kidney disease and our data to date show clearly that inhibition of glutaminyl-cyclases with varoglutamstat is a promising new approach to treat diabetic kidney disease and other chronic diseases of the kidney. Every step forward strengthens our belief that, with varoglutamstat, we have a unique opportunity to develop a game-changing medicine with the potential to go beyond current standard of care and meaningfully improve kidney function in people with kidney disease.”
Vivoryon is planning to confirm the previously reported compelling data from its two independent Phase 2 studies, VIVIAD and VIVA-MIND, by conducting a dedicated Phase 2b clinical study in patients with advanced diabetic kidney disease (DKD) stage 3b/4. Initiation of the Phase 2b and all future studies is subject to additional funding and/or partnership, which Vivoryon continues to actively explore.
###
VIVIAD (NCT04498650) is a randomized clinical trial (Phase 2b) in 259 patients with early Alzheimer’s disease treated with 300 or 600 mg varoglutamstat, or placebo, BID for 48-96 weeks. Measurement of eGFR and biomarkers of inflammation were prospectively defined. pE-CCL2 serum levels were measured at baseline and at week 48 with an ELISA. Individual patient slopes of eGFR (MDRD formula) were calculated using random-coefficient analysis. Spearman correlations were calculated with R.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com
Investor Contact
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com
Media Contact
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti